关注
Giulia Orsi
Giulia Orsi
IRCCS San Raffaele Scientific Institute - Vita Salute University
在 hsr.it 的电子邮件经过验证
标题
引用次数
引用次数
年份
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients
F Tovoli, L Ielasi, A Casadei-Gardini, A Granito, FG Foschi, G Rovesti, ...
Journal of hepatology 71 (6), 1175-1183, 2019
702019
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
C Tomasello, C Baldessari, M Napolitano, G Orsi, G Grizzi, F Bertolini, ...
Critical reviews in oncology/hematology 123, 149-161, 2018
622018
Gastric cancer: translating novels concepts into clinical practice
M Salati, G Orsi, E Smyth, G Beretta, F De Vita, M Di Bartolomeo, ...
Cancer treatment reviews 79, 101889, 2019
612019
Soluble TRAIL armed human MSC as gene therapy for pancreatic cancer
C Spano, G Grisendi, G Golinelli, F Rossignoli, M Prapa, M Bestagno, ...
Scientific reports 9 (1), 1788, 2019
612019
Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy
F Rossignoli, G Grisendi, C Spano, G Golinelli, A Recchia, G Rovesti, ...
Cancer Gene Therapy 26 (1), 11-16, 2019
532019
MSC-delivered soluble TRAIL and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma
F Rossignoli, C Spano, G Grisendi, EM Foppiani, G Golinelli, I Mastrolia, ...
Theranostics 9 (2), 436, 2019
482019
GD2 expression in breast cancer
G Orsi, M Barbolini, G Ficarra, G Tazzioli, P Manni, T Petrachi, I Mastrolia, ...
Oncotarget 8 (19), 31592, 2017
462017
Impact of baseline characteristics on the overall survival of HCC patients treated with sorafenib: ten years of experience
G Rovesti, G Orsi, A Kalliopi, C Vivaldi, G Marisi, L Faloppi, FG Foschi, ...
Gastrointestinal Tumors 6 (3-4), 92-107, 2019
362019
Lenvatinib as a therapy for unresectable hepatocellular carcinoma
A Spallanzani, G Orsi, K Andrikou, F Gelsomino, M Rimini, L Riggi, ...
Expert Review of Anticancer Therapy 18 (11), 1069-1076, 2018
342018
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
G Marisi, E Petracci, F Raimondi, L Faloppi, FG Foschi, G Lauletta, ...
Cancers 11 (7), 1023, 2019
292019
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
U Peretti, A Cavaliere, M Niger, G Tortora, MC Di Marco, MG Rodriquenz, ...
ESMO open 6 (1), 100032, 2021
232021
EUS-guided gastroenterostomy for management of malignant gastric outlet obstruction: A prospective cohort study with matched comparison with enteral stenting
G Vanella, G Dell’Anna, G Capurso, P Maisonneuve, M Bronswijk, ...
Gastrointestinal Endoscopy 98 (3), 337-347. e5, 2023
212023
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants
M Macchini, F Centonze, U Peretti, G Orsi, AM Militello, MM Valente, ...
Cancer Treatment Reviews 100, 102262, 2021
212021
Prognostic role of blood eosinophil count in patients with sorafenib-treated hepatocellular carcinoma
G Orsi, F Tovoli, V Dadduzio, C Vivaldi, O Brunetti, L Ielasi, F Conti, ...
Targeted Oncology 15, 773-785, 2020
172020
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter …
A Casadei-Gardini, G Marisi, V Dadduzio, L Gramantieri, L Faloppi, P Ulivi, ...
Clinical Cancer Research 26 (17), 4485-4493, 2020
162020
Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity
M Salati, G Orsi, LR Bonetti, F Di Benedetto, G Longo, S Cascinu
World Journal of Gastrointestinal Oncology 9 (3), 135, 2017
162017
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
G Orsi, M Di Marco, A Cavaliere, M Niger, S Bozzarelli, G Giordano, ...
ESMO open 6 (5), 100238, 2021
142021
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib
A Casadei-Gardini, V Dadduzio, G Rovesti, G Cabibbo, R Vukotic, ...
Medicine 99 (22), e19958, 2020
132020
The impact of nutritional status on pancreatic cancer therapy
G Capurso, N Pecorelli, A Burini, G Orsi, D Palumbo, M Macchini, R Mele, ...
Expert Review of Anticancer Therapy 22 (2), 155-167, 2022
122022
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma
I Trestini, L Carbognin, U Peretti, I Sperduti, A Caldart, D Tregnago, ...
Frontiers in Oncology 11, 688889, 2021
122021
系统目前无法执行此操作,请稍后再试。
文章 1–20